-
Product Insights
New![]()
Altus CBRE IM Community Solar PV Park
Altus CBRE IM Community Solar PV Park is a solar PV project located in Maryland, United States. The project is owned by Altus Power Inc; CBRE Group Inc and is developed by Altus Power Inc. The project is at the permitting stage. Empower your strategies with our Altus CBRE IM Community Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IM-19 in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IM-19 in Follicular Lymphoma Drug Details: IM-19 is under development for the treatment of relapsed or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IM-19 in Mantle Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IM-19 in Mantle Cell Lymphoma Drug Details: IM-19 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IM-21 in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IM-21 in Refractory Multiple Myeloma Drug Details: IM-21 is under development for the treatment of...
-
Track & Monitor
![]()
Innovation in banking: IM trading platforms
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the banking industry’s IM trading platforms innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Primary Progressive Multiple Sclerosis (PPMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMS-001 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:IMS-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:IMS-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IM-19 in Primary Mediastinal B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IM-19 in Primary Mediastinal B-Cell Lymphoma Drug Details: IM-19 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:IMS-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IM-19 in Diffuse Large B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IM-19 in Diffuse Large B-Cell Lymphoma Drug Details: IM-19 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.